
  
    
      
        
        Smoking_NN is_VBZ the_DT single_JJ largest_JJS preventable_JJ cause_NN of_IN disease_NN and_CC premature_JJ death_NN ,_,
        according_VBG to_TO the_DT World_NNP Health_NNP Organization_NNP ._. Smoking-related_NNP diseases_NNS kill_VBP one_CD in_IN ten_CD adults_NNS
        globally_RB ,_, i_NNP ._. e_SYM ._. ,_, 4_CD million_CD deaths_NNS annually_RB ;_: by_IN 2030_CD ,_, if_IN current_JJ trends_NNS continue_VBP ,_, smoking_NN
        will_MD kill_VB one_CD in_IN six_CD people_NNS ._. Smoking_NN is_VBZ a_DT prime_JJ factor_NN in_IN heart_NN disease_NN ,_, stroke_NN ,_, and_CC
        chronic_JJ lung_NN disease_NN ,_, which_WDT cost_VBP the_DT United_NNP States_NNPS more_JJR than_IN $_$ 150_CD billion_CD a_DT year_NN ._. The_DT
        relationship_NN between_IN smoking_NN and_CC cardiovascular_JJ disease_NN is_VBZ well_RB documented_VBN ,_, as_IN is_VBZ the_DT
        association_NN of_IN smoking_NN with_IN increased_VBN levels_NNS of_IN inflammatory_JJ markers_NNS and_CC accelerated_VBD
        atherosclerosis_NNS ._. It_PRP is_VBZ also_RB well_RB known_VBN that_IN when_WRB smokers_NNS quit_VBD ,_, their_PRP$ risk_NN of_IN mortality_NN and_CC
        future_JJ cardiac_JJ events_NNS declines_NNS ,_, but_CC there_EX is_VBZ little_JJ data_NNS quantifying_VBG the_DT rate_NN of_IN this_DT risk_NN
        reduction_NN ._.
        Smoking_NN triggers_VBZ an_DT immunologic_JJ response_NN to_TO vascular_NN injury_NN ,_, which_WDT is_VBZ associated_VBN with_IN
        increased_VBN levels_NNS of_IN inflammatory_JJ markers_NNS ,_, such_JJ as_IN C-_NNP reactive_JJ protein_NN and_CC white_JJ blood_NN cell_NN
        count_NN ._. Several_JJ studies_NNS have_VBP shown_VBN that_IN such_JJ markers_NNS predict_VBP future_JJ cardiovascular_JJ events_NNS ._.
        Markers_NNP such_JJ as_IN C-_NNP reactive_JJ protein_NN are_VBP also_RB increasingly_RB implicated_VBN in_IN the_DT pathogenesis_NNS of_IN
        atherosclerosis_NNS ._. There_EX are_VBP ,_, however_RB ,_, still_RB some_DT gaps_NNS in_IN our_PRP$ knowledge_NN of_IN cardiovascular_JJ
        disease_NN ,_, smoking_NN ,_, and_CC the_DT predictive_JJ use_NN of_IN such_JJ markers_NNS ._. For_IN example_NN ,_, few_JJ studies_NNS have_VBP
        examined_VBN the_DT impact_NN of_IN smoking_NN cessation_NN on_IN levels_NNS of_IN inflammatory_JJ markers_NNS or_CC on_IN
        cardiovascular_JJ risk_NN reduction_NN ;_: the_DT level_NN and_CC rate_NN at_IN which_WDT the_DT inflammatory_JJ response_NN
        subsides_NNS following_VBG smoking_NN cessation_NN is_VBZ also_RB uncertain_JJ ._. Furthermore_RB ,_, whether_IN traditional_JJ
        risk_NN factors_NNS can_MD explain_VB the_DT decline_NN in_IN cardiovascular_JJ risk_NN following_VBG smoking_NN cessation_NN is_VBZ
        also_RB unclear_JJ ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Arvind_NNP Bakhru_NNP and_CC Thomas_NNP Erlinger_NNP investigate_VB the_DT
        association_NN between_IN smoking_NN and_CC smoking_NN cessation_NN and_CC levels_NNS of_IN inflammatory_JJ markers_NNS and_CC
        cardiovascular_JJ risk_NN factors_NNS ._. Data_NNP were_VBD gathered_VBN on_IN 15_CD ,_, 489_CD US_NNP adults_NNS between_IN 1988_CD and_CC 1994_CD
        in_IN the_DT Third_NNP National_NNP Health_NNP and_CC Nutrition_NNP Examination_NNP Survey_NNP ._. Of_IN these_DT ,_, 7_CD ,_, 665_CD were_VBD
        classified_VBN as_RB never_RB smokers_NNS ,_, 3_CD ,_, 459_CD were_VBD former_JJ smokers_NNS ,_, and_CC 4_CD ,_, 365_CD were_VBD current_JJ smokers_NNS ._.
        The_DT investigators_NNS focused_VBN on_IN changes_NNS in_IN C-_NNP reactive_JJ protein_NN ,_, white_JJ blood_NN cell_NN count_NN ,_,
        albumin_NN ,_, and_CC fibrinogen_NN ,_, and_CC the_DT traditional_JJ risk_NN factors—total_NN cholesterol_NN ,_, high-density_JJ
        lipoprotein_NN cholesterol_NN ,_, triglycerides_NNS ,_, systolic_JJ blood_NN pressure_NN ,_, and_CC diabetes—that_NN occurred_VBD
        with_IN decreased_VBD smoking_VBG intensity_NN and_CC increased_VBN time_NN since_IN smoking_NN cessation_NN ._. They_PRP found_VBD
        that_IN inflammatory_JJ markers_NNS had_VBD a_DT dose-dependent_JJ and_CC temporal_JJ relationship_NN to_TO smoking_NN and_CC
        smoking_NN cessation_NN ._. They_PRP noted_VBD that_IN both_DT inflammatory_JJ and_CC traditional_JJ risk_NN factors_NNS improved_VBN
        with_IN less_JJR smoking_NN ,_, but_CC as_IN the_DT time_NN since_IN smokers_NNS quit_VBD increased_VBN ,_, inflammatory_JJ markers_NNS
        resolved_VBD more_RBR slowly_RB than_IN traditional_JJ cardiovascular_JJ risk_NN factors_NNS ._. Still_RB ,_, the_DT
        smoking-associated_JJ inflammatory_JJ response_NN returned_VBD to_TO normal_JJ within_IN five_CD years_NNS after_IN smokers_NNS
        quit_VBD ,_, suggesting_VBG that_IN the_DT vascular_NN effects_NNS were_VBD reversible_JJ and_CC that_IN cardiovascular_JJ risk_NN
        subsides_NNS gradually_RB with_IN reduced_VBN exposure_NN ._.
        The_DT authors_NNS conclude_VBP that_IN these_DT findings_NNS support_VBP the_DT hypothesis_NNS that_IN cardiovascular_JJ risk_NN
        falls_VBZ as_IN inflammatory_JJ response_NN falls_VBZ ,_, and_CC that_IN inflammatory_JJ markers_NNS are_VBP good_JJ indicators_NNS of_IN
        this_DT risk_NN reduction_NN ._. Despite_IN limitations_NNS of_IN the_DT study_NN ,_, including_VBG possible_JJ errors_NNS from_IN
        self-reporting_JJ and_CC lack_NN of_IN data_NNS on_IN second-hand_JJ smoke_NN and_CC newer_JJR measures_NNS such_JJ as_IN
        interleukin-_NN 6_CD and_CC high-sensitivity_JJ C-_NNP reactive_JJ protein_NN ,_, the_DT inflammatory_JJ markers_NNS studied_VBN
        here_RB demonstrated_VBD a_DT much_RB clearer_JJR trend_NN and_CC longer-lasting_JJ effect_NN after_IN smoking_VBG cessation_NN
        than_IN traditional_JJ risk_NN factors_NNS ,_, and_CC hence_RB were_VBD more_RBR useful_JJ and_CC accurate_JJ markers_NNS of_IN
        disease_NN ._.
        As_IN with_IN related_VBN studies_NNS ,_, these_DT results_NNS suggest_VBP that_DT smoking_NN cessation_NN should_MD be_VB a_DT more_RBR
        prominent_JJ goal_NN of_IN public_JJ policy_NN ,_, and_CC the_DT authors_NNS conclude_VBP that_IN policymakers_NNS must_MD pursue_VB
        smoking_VBG cessation_NN plans_NNS as_IN an_DT opportunity_NN to_TO make_VB savings_NNS on_IN health_NN care_NN through_IN
        cardiovascular_JJ risk_NN reduction_NN ._. Further_RB research_NN should_MD explore_VB the_DT acute_JJ phase_NN response_NN in_IN
        the_DT months_NNS after_IN smoking_VBG cessation_NN ,_, which_WDT this_DT and_CC other_JJ studies_NNS have_VBP not_RB been_VBN able_JJ to_TO
        study_VB adequately_RB ._.
      
    
  
